Partnerships and co-selling KPIs and metrics that matter for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install partnerships and co-selling has to reflect that reality from day one.

Almost every dashboard we inherit for partnerships and co-selling is measuring the wrong things. This is the short list that predicts outcomes.

Headline metric: sourced and influenced pipeline from partners. Everything else is diagnostic.

Leading indicators, three of them: trigger volume, response quality, and time from trigger to first human touch. Any one going the wrong way predicts the headline moving the wrong way inside three weeks.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Partnerships and co-selling is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Lagging indicators: pipeline created, opportunity conversion, and cycle length. These confirm what the leading indicators already told you.

Vanity metrics to stop tracking: raw opens, raw sends, and top-of-funnel counts unattached to fit. They reward volume and hide waste.

Cadence: leading indicators daily, headline weekly, lagging monthly. Anything more often creates noise; anything less loses the drift.

The single dashboard rule: if a metric on your board has not driven a decision in the last quarter, delete it. Partnerships and co-selling thrives on fewer, sharper numbers.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing partnerships and co-selling properly rather than half-heartedly across three vendors.